Tango Therapeutics, Inc. (TNGX) Tops Q3 EPS by 10c

Tango Therapeutics, Inc. (NASDAQ: TNGX) reported Q3 EPS of ($0.27), $0.10 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $11.61 million versus the consensus estimate of $8.07 million.

For earnings history and earnings-related data on Tango Therapeutics, Inc. (TNGX) click here.

You May Also Be Interested In

• Jefferies Financial Group (JEF) Tops Q3 EPS by 8c
• Pathfinder Bancorp (PBHC) Declares $0.10 Quarterly Dividend; 2.3% Yield
• AAR To Pay $1.8B For Stake In Aircraft-maintenance Company - WSJ